RBCx

Making the founder to CEO transition can be a major milestone in a founder's journey. Here's how to navigate that change and take your vision to the next level. Key takeaways Founder-led companies thrive, but there are limits: Founder-led unicorns tend to

Key takeaways Scaling successfully requires securing capital, knowing your market, and - most importantly - bringing together the right talent Canadian startups need to adopt a global mindset from the very beginning True success is built on learning from

Key takeaways Mental resilience is just as integral to success as physical, according to Canadian Olympic sprinter Duan Asemota. Athletes and founders alike rely on the support of a trusted team to face tough challenges and achieve peak performance. Adopt

Key takeaways New RBCx data shows far fewer companies are raising heading into H2 2026. Capital is concentrating in larger funds. Emerging managers are facing an estimated 36% funding shortfall, limiting an important source of early-stage risk capital. Fe

Key takeaways Canadian VC fundraising hit just $2 billion in 2025 - far below the $7+ billion peak of 2021-2022. The top five funds captured around 83% of all capital raised indicating a trend towards capital concentration. Emerging managers raised only $

A discussion on the current state of fundraising with leading minds in the venture capital industry The world of venture capital is constantly evolving, with companies always looking to stand out among a bustling market. Founders face many challenges as t

Key takeaways What Investors Should Watch: Pricing volatility is the new risk premium: When investors cannot confidently model U.S. pricing and reimbursement, discount rates rise and marginal programs fall below the funding line. Pricing uncertainty kills

A roundtable discussion on scale and its challenges with leading innovators in the venture capital ecosystem In an ever-evolving business environment, how do savvy investors and entrepreneurs tackle questions of scale and growth? How can companies uphold

Drug pricing policies are reshaping the life sciences landscape in many ways. From the United States' Most-Favored-Nation (MFN) policy to evolving international frameworks, these decisions are influencing everything from commercialization strategies to in